Summit Therapeutics Stock (NASDAQ:SMMT)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$20.00

52W Range

$1.89 - $33.89

50D Avg

$21.47

200D Avg

$10.52

Market Cap

$13.72B

Avg Vol (3M)

$5.19M

Beta

-0.92

Div Yield

-

SMMT Company Profile


Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

105

IPO Date

Mar 05, 2015

Website

SMMT Performance


SMMT Financial Summary


Dec 23Dec 22Dec 21
Revenue-$704.29K$1.81M
Operating Income$1.00M$-72.09M$-86.19M
Net Income$-614.93M$-74.38M$-86.15M
EBITDA$1.00M$-60.80M$-86.19M
Basic EPS-$-0.38$-0.65
Diluted EPS-$-0.38$-0.65

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 1:27 PM
Q1 24May 01, 24 | 12:00 AM
Q4 23Feb 20, 24 | 1:54 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
PHIOPhio Pharmaceuticals Corp.
KRONKronos Bio, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
NKTXNkarta, Inc.
OCEAOcean Biomedical, Inc.
KZRKezar Life Sciences, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.